Primary analysis of BERENICE: a phase two cardiac safety study of Pertuzumab, Trastuzumab, and neoadjuvant Anthracycline-based CT in patients with locally advanced, inflammatory or early-stage, unilateral, and invasive HER2+ breast cancer.
Citation: Unpublished 2017/10/03Form of publication: Poster PresentationYear: 2017Conference information: Washington Cancer Institute: MedStar Health Research Symposium, North Bethesda, MD., Fiscal year: FY2018Local accession number: A2017_248Date added to catalog: 2018-08-01| Item type | Current library | Collection | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
| Poster Presentation | MedStar Authors Catalog | Poster | Available |